Clinical Trials Browser

Phase 2 × Cushing Syndrome × 1 year × Clear all

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2

NCT03604198 2026-02-19

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

NCT07104812 2026-02-11

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Phase 2 Recruiting

15 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

NCT06246357 2025-12-09

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Phase 2 Recruiting

80 enrolled

Adenoma, Cushing Syndrome, Hyperaldosteronism

NCT05307328 2025-10-08

RESCUE

Phase 2 Completed

26 enrolled

Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary ACTH Hypersecretion

NCT06106295 2025-09-22

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

Phase 2 Active not recruiting

30 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

NCT07138274 2025-08-22

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

Phase 2 Not yet recruiting

90 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

Clinical Trials

CAPTAIN-T2D

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

RESCUE

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS